Study of the efficiency and safety of Ladasten therapy in patients with cardiovascular disease
| Autor: | E. A Makukh, Abram Syrkin, F. Yu. Kopylov, Yu. M. Nikitina |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Drug
lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty lcsh:RC648-665 Cardiovascular pathology business.industry media_common.quotation_subject cardiovascular pathology Disease lcsh:Diseases of the endocrine glands. Clinical endocrinology antiasthenic means Tolerability lcsh:RC666-701 medicine In patient asthenia Intensive care medicine business media_common |
| Zdroj: | КардиоСоматика, Vol 1, Iss 1, Pp 57-61 (2010) |
| ISSN: | 2658-5707 2221-7185 |
| DOI: | 10.26442/cs44966 |
| Popis: | A trial was carried out to study the efficiency and safety of therapy with the new antiasthenic drug Ladasten. The findings suggest its high safety and efficiency and good tolerability of Ladasten in the treatment of asthenia and asthenic spectrum disorders, the development of which is associated with cardiovascular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|